Skip to Content
Merck
All Photos(1)

Key Documents

01-6635

Sigma-Aldrich

Arsenic(III) oxide

SAJ first grade, ≥99.0%

Synonym(s):

Arsenic trioxide, Arsenous acid

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
As2O3
CAS Number:
Molecular Weight:
197.84
EC Number:
MDL number:
UNSPSC Code:
12352103
PubChem Substance ID:

grade

SAJ first grade

vapor pressure

0.000001 hPa ( 66 °C)

Assay

≥99.0%

form

powder

availability

available only in Japan

SMILES string

O=[As]O[As]=O

InChI

1S/As2O3/c3-1-5-2-4

InChI key

IKWTVSLWAPBBKU-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1

Target Organs

Respiratory system,Cardio-vascular system,Gastrointestinal tract

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yanfei Jia et al.
PloS one, 8(1), e54774-e54774 (2013-02-06)
Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC), represented by the production of AFP, has a more aggressive behavior than common gastric cancer. The underlying mechanisms are not well understood. Arsenic trioxide (As(2)O(3)) is used clinically to treat acute promyelocytic leukemia(APL) and has
Liangchun Hao et al.
Journal of pediatric hematology/oncology, 35(2), e67-e70 (2013-02-16)
The aim of this study was to investigate the hepatotoxicity induced by arsenic trioxide (As2O3) at a therapeutic dose for pediatric acute promyelocytic leukemia (APL). A total of APL patients received As2O3 treatment by IV drip. Hepatotoxicity was monitored based
Masamitsu Yanada et al.
Blood, 121(16), 3095-3102 (2013-02-16)
The optimal treatments for relapsed acute promyelocytic leukemia (APL) remain equivocal. We conducted a phase 2 study to evaluate the efficacy and feasibility of a sequential treatment consisting of induction and consolidation with arsenic trioxide (ATO), peripheral blood stem cell
Cui Li et al.
Toxicology letters, 219(3), 223-230 (2013-04-02)
Arsenic trioxide (As2O3; ATO) is clinically effective in treating acute promyelocytic leukemia (APL); however, it frequently causes cardiotoxic effects. This study was designed to investigate whether ATO could induce apoptosis of cardiac fibroblasts (CFs) that play very important roles in
Athena Kritharis et al.
Annals of hematology, 92(6), 719-730 (2013-03-16)
For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service